Christopher And Dana Reeve Foundation Response To FDA Clearance Of Geron’s Clinical Trial

Peter T. Wilderotter, president and CEO of the Christopher & Dana Reeve Foundation, issued the following statement in response to FDA clearance of Geron’s human clinical trial of embryonic stem cell-based therapy: “This is an exciting first step for Geron and for spinal cord injured patients whose lives may improve due to advances in medical research.

More: continued here

Filed under: Stem Cell Research on January 25th, 2009